Free Trial

LifeMD (LFMD) Competitors

LifeMD logo
$13.62 -0.13 (-0.95%)
As of 06/30/2025 04:00 PM Eastern

LFMD vs. PRVA, CON, SGRY, ADUS, VCYT, PACS, WGS, LFST, ARDT, and PGNY

Should you be buying LifeMD stock or one of its competitors? The main competitors of LifeMD include Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Addus HomeCare (ADUS), Veracyte (VCYT), PACS Group (PACS), GeneDx (WGS), LifeStance Health Group (LFST), Ardent Health (ARDT), and Progyny (PGNY). These companies are all part of the "healthcare" industry.

LifeMD vs. Its Competitors

LifeMD (NASDAQ:LFMD) and Privia Health Group (NASDAQ:PRVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

LifeMD has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Privia Health Group has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Privia Health Group has a net margin of 0.87% compared to LifeMD's net margin of -4.58%. Privia Health Group's return on equity of 2.32% beat LifeMD's return on equity.

Company Net Margins Return on Equity Return on Assets
LifeMD-4.58% N/A -15.19%
Privia Health Group 0.87%2.32%1.38%

In the previous week, LifeMD and LifeMD both had 4 articles in the media. Privia Health Group's average media sentiment score of 0.93 beat LifeMD's score of 0.59 indicating that Privia Health Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LifeMD
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Privia Health Group
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Privia Health Group has higher revenue and earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$212.45M2.91-$18.88M-$0.34-40.06
Privia Health Group$1.74B1.61$14.39M$0.12191.67

LifeMD presently has a consensus price target of $12.00, suggesting a potential downside of 11.89%. Privia Health Group has a consensus price target of $27.77, suggesting a potential upside of 20.74%. Given Privia Health Group's higher probable upside, analysts clearly believe Privia Health Group is more favorable than LifeMD.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeMD
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Privia Health Group
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
3.00

35.5% of LifeMD shares are held by institutional investors. Comparatively, 94.5% of Privia Health Group shares are held by institutional investors. 18.4% of LifeMD shares are held by insiders. Comparatively, 10.7% of Privia Health Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Privia Health Group beats LifeMD on 11 of the 14 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Sign up to receive the latest news and ratings for LFMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LFMD vs. The Competition

MetricLifeMDMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$624.91M$7.36B$5.46B$8.90B
Dividend YieldN/A2.79%5.36%4.13%
P/E Ratio-40.0627.6926.4419.67
Price / Sales2.9133.98405.32110.29
Price / CashN/A18.5725.8827.49
Price / Book-151.336.457.945.42
Net Income-$18.88M$230.16M$3.15B$248.34M
7 Day Performance-3.06%0.65%0.63%0.81%
1 Month Performance12.10%4.98%4.96%5.01%
1 Year Performance100.29%31.87%32.55%18.10%

LifeMD Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LFMD
LifeMD
0.8256 of 5 stars
$13.62
-0.9%
$12.00
-11.9%
+98.5%$624.91M$212.45M-40.06230Gap Up
PRVA
Privia Health Group
3.5164 of 5 stars
$21.61
-1.1%
$27.77
+28.5%
+32.3%$2.66B$1.74B182.081,140
CON
Concentra Group Holdings Parent
2.9745 of 5 stars
$20.95
+1.0%
$28.50
+36.0%
N/A$2.66B$1.90B15.6311,250
SGRY
Surgery Partners
2.2998 of 5 stars
$20.20
+4.7%
$33.56
+66.1%
-6.6%$2.47B$3.11B-13.2015,000
ADUS
Addus HomeCare
4.7476 of 5 stars
$113.01
-0.7%
$142.57
+26.2%
-0.8%$2.09B$1.15B25.5149,703Positive News
Analyst Upgrade
VCYT
Veracyte
3.4666 of 5 stars
$26.71
+1.2%
$40.90
+53.1%
+24.7%$2.07B$445.76M65.15790Analyst Downgrade
PACS
PACS Group
2.7501 of 5 stars
$12.77
-3.1%
$34.29
+168.5%
-56.2%$2.01B$3.11B0.0032,433
WGS
GeneDx
1.9148 of 5 stars
$79.71
+19.0%
$86.75
+8.8%
+253.1%$1.91B$305.45M73.631,200Analyst Forecast
Gap Down
High Trading Volume
LFST
LifeStance Health Group
2.4157 of 5 stars
$4.96
+2.7%
$8.50
+71.4%
+5.3%$1.88B$1.25B0.0010,218
ARDT
Ardent Health
3.4157 of 5 stars
$12.94
-0.8%
$20.67
+59.7%
N/A$1.87B$5.97B7.9524,900
PGNY
Progyny
1.219 of 5 stars
$20.79
-0.9%
$23.45
+12.8%
-23.1%$1.80B$1.17B39.58310

Related Companies and Tools


This page (NASDAQ:LFMD) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners